But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Regulators in the United Kingdom issued guidance on Thursday, warning that weight loss and diabetes medications may weaken ...

Cirius Therapeutics, Inc.,  developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced ...

Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Healthtm Personalized Health & Medicine Platform* (Lilly Health app) with its ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...